REGENXBIO Inc.
General ticker "RGNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $449.3M (TTM average)
REGENXBIO Inc. follows the US Stock Market performance with the rate: 57.3%.
Estimated limits based on current volatility of 4.7%: low 10.25$, high 11.59$
Factors to consider:
- Total employees count: 353 (-66.1%) as of 2024
- Top business risk factors: Operational and conduct risks, Clinical trial delays and efficacy/safety demonstration, Product recalls, Cybersecurity threats, Regulatory and compliance
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.17$, 12.01$]
- 2025-12-31 to 2026-12-31 estimated range: [4.98$, 11.38$]
Financial Metrics affecting the RGNX estimates:
- Negative: with PPE of -1.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -46.40 <= 0
- Positive: Investing cash flow per share per price, % of 27.73 > -0.63
- Positive: Inventory ratio change, % of 0.03 <= 0.79
- Positive: 42.77 < Shareholder equity ratio, % of 55.72 <= 64.37
Short-term RGNX quotes
Long-term RGNX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $112.72MM | $90.24MM | $83.33MM |
| Operating Expenses | $375.60MM | $358.37MM | $316.67MM |
| Operating Income | $-262.88MM | $-268.13MM | $-233.35MM |
| Non-Operating Income | $-17.53MM | $4.48MM | $6.24MM |
| Interest Expense | $23.25MM | $6.86MM | $12.66MM |
| R&D Expense | $242.45MM | $232.27MM | $208.52MM |
| Income(Loss) | $-280.40MM | $-263.65MM | $-227.10MM |
| Taxes | $-0.08MM | $-0.15MM | $0.00MM |
| Profit(Loss)* | $-280.32MM | $-263.49MM | $-227.10MM |
| Stockholders Equity | $516.20MM | $311.74MM | $259.65MM |
| Assets | $833.27MM | $573.97MM | $465.99MM |
| Operating Cash Flow | $-207.49MM | $-218.41MM | $-173.12MM |
| Capital expenditure | $30.72MM | $9.96MM | $2.44MM |
| Investing Cash Flow | $-11.93MM | $190.94MM | $103.45MM |
| Financing Cash Flow | $-28.84MM | $-34.97MM | $92.68MM |
| Earnings Per Share** | $-6.50 | $-6.02 | $-4.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.